Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
J Gen Virol ; 105(2)2024 02.
Artículo en Inglés | MEDLINE | ID: mdl-38305775

RESUMEN

Filoviridae is a family of negative-sense RNA viruses with genomes of about 13.1-20.9 kb that infect fish, mammals and reptiles. The filovirid genome is a linear, non-segmented RNA with five canonical open reading frames (ORFs) that encode a nucleoprotein (NP), a polymerase cofactor (VP35), a glycoprotein (GP1,2), a transcriptional activator (VP30) and a large protein (L) containing an RNA-directed RNA polymerase (RdRP) domain. All filovirid genomes encode additional proteins that vary among genera. Several filovirids (e.g., Ebola virus, Marburg virus) are pathogenic for humans and highly virulent. This is a summary of the International Committee on Taxonomy of Viruses (ICTV) Report on the family Filoviridae, which is available at www.ictv.global/report/filoviridae.


Asunto(s)
Ebolavirus , Marburgvirus , Rhabdoviridae , Animales , Humanos , Ebolavirus/genética , Rhabdoviridae/genética , Filogenia , Genoma Viral , Replicación Viral , Mamíferos/genética
2.
Arch Virol ; 168(8): 220, 2023 Aug 03.
Artículo en Inglés | MEDLINE | ID: mdl-37537381

RESUMEN

The International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group continues to prospectively refine the established nomenclature for taxa included in family Filoviridae in an effort to decrease confusion of genus, species, and virus names and to adhere to amended stipulations of the International Code of Virus Classification and Nomenclature (ICVCN). Recently, the genus names Ebolavirus and Marburgvirus were changed to Orthoebolavirus and Orthomarburgvirus, respectively. Additionally, all established species names in family Filoviridae now adhere to the ICTV-mandated binomial format. Virus names remain unchanged and valid. Here, we outline the revised taxonomy of family Filoviridae as approved by the ICTV in April 2023.


Asunto(s)
Ebolavirus , Filoviridae , Marburgvirus , Virus
3.
Proc Natl Acad Sci U S A ; 114(5): 938-943, 2017 01 31.
Artículo en Inglés | MEDLINE | ID: mdl-28096420

RESUMEN

Rift Valley fever (RVF) is a vector-borne viral disease widespread in Africa. The primary cycle involves mosquitoes and wild and domestic ruminant hosts. Humans are usually contaminated after contact with infected ruminants. As many environmental, agricultural, epidemiological, and anthropogenic factors are implicated in RVF spread, the multidisciplinary One Health approach was needed to identify the drivers of RVF epidemics in Madagascar. We examined the environmental patterns associated with these epidemics, comparing human and ruminant serological data with environmental and cattle-trade data. In contrast to East Africa, environmental drivers did not trigger the epidemics: They only modulated local Rift Valley fever virus (RVFV) transmission in ruminants. Instead, RVFV was introduced through ruminant trade and subsequent movement of cattle between trade hubs caused its long-distance spread within the country. Contact with cattle brought in from infected districts was associated with higher infection risk in slaughterhouse workers. The finding that anthropogenic rather than environmental factors are the main drivers of RVF infection in humans can be used to design better prevention and early detection in the case of RVF resurgence in the region.


Asunto(s)
Enfermedades de los Bovinos/epidemiología , Fiebre del Valle del Rift/epidemiología , Mataderos , Animales , Bovinos , Enfermedades de los Bovinos/sangre , Enfermedades de los Bovinos/inmunología , Enfermedades de los Bovinos/transmisión , Comercio , Epidemias , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Madagascar/epidemiología , Fiebre del Valle del Rift/sangre , Fiebre del Valle del Rift/inmunología , Fiebre del Valle del Rift/transmisión , Virus de la Fiebre del Valle del Rift/inmunología , Estudios Seroepidemiológicos , Tiempo (Meteorología)
4.
J Gen Virol ; 100(6): 911-912, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-31021739

RESUMEN

Members of the family Filoviridae produce variously shaped, often filamentous, enveloped virions containing linear non-segmented, negative-sense RNA genomes of 15-19 kb. Several filoviruses (e.g., Ebola virus) are pathogenic for humans and are highly virulent. Several filoviruses infect bats (e.g., Marburg virus), whereas the hosts of most other filoviruses are unknown. This is a summary of the International Committee on Taxonomy of Viruses (ICTV) Report on Filoviridae, which is available at www.ictv.global/report/filoviridae.


Asunto(s)
Filoviridae/clasificación , Animales , Filoviridae/genética , Genoma Viral/genética , Humanos , ARN Viral/genética
5.
6.
Arch Virol ; 164(4): 1233-1244, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30663023

RESUMEN

In October 2018, the order Mononegavirales was amended by the establishment of three new families and three new genera, abolishment of two genera, and creation of 28 novel species. This article presents the updated taxonomy of the order Mononegavirales as now accepted by the International Committee on Taxonomy of Viruses (ICTV).


Asunto(s)
Mononegavirales/clasificación , Mononegavirales/genética , Mononegavirales/aislamiento & purificación , Filogenia , Virología/organización & administración
7.
Arch Virol ; 163(8): 2283-2294, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-29637429

RESUMEN

In 2018, the order Mononegavirales was expanded by inclusion of 1 new genus and 12 novel species. This article presents the updated taxonomy of the order Mononegavirales as now accepted by the International Committee on Taxonomy of Viruses (ICTV) and summarizes additional taxonomic proposals that may affect the order in the near future.


Asunto(s)
Mononegavirales/clasificación , Animales , Humanos , Mononegavirales/genética , Mononegavirales/aislamiento & purificación , Infecciones por Mononegavirales/veterinaria , Infecciones por Mononegavirales/virología , Filogenia
8.
Lancet Infect Dis ; 2024 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-38964363

RESUMEN

In 2016, WHO designated Lassa fever a priority disease for epidemic preparedness as part of the WHO Blueprint for Action to Prevent Epidemics. One aspect of preparedness is to promote development of effective medical countermeasures (ie, diagnostics, therapeutics, and vaccines) against Lassa fever. Diagnostic testing for Lassa fever has important limitations and key advancements are needed to ensure rapid and accurate diagnosis. Additionally, the only treatment available for Lassa fever is ribavirin, but controversy exists regarding its effectiveness. Finally, no licensed vaccines are available for the prevention and control of Lassa fever. Ongoing epidemiological and behavioural studies are also crucial in providing actionable information for medical countermeasure development, use, and effectiveness in preventing and treating Lassa fever. This Personal View provides current research priorities for development of Lassa fever medical countermeasures based on literature published primarily in the last 5 years and consensus opinion of 20 subject matter experts with broad experience in public health or the development of diagnostics, therapeutics, and vaccines for Lassa fever. These priorities provide an important framework to ensure that Lassa fever medical countermeasures are developed and readily available for use in endemic and at-risk areas by the end of the decade.

9.
Lancet Infect Dis ; 2024 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-38964362

RESUMEN

Nipah virus causes highly lethal disease, with case-fatality rates ranging from 40% to 100% in recognised outbreaks. No treatments or licensed vaccines are currently available for the prevention and control of Nipah virus infection. In 2019, WHO published an advanced draft of a research and development roadmap for accelerating development of medical countermeasures, including diagnostics, therapeutics, and vaccines, to enable effective and timely emergency response to Nipah virus outbreaks. This Personal View provides an update to the WHO roadmap by defining current research priorities for development of Nipah virus medical countermeasures, based primarily on literature published in the last 5 years and consensus opinion of 15 subject matter experts with broad experience in development of medical countermeasures for Nipah virus or experience in the epidemiology, ecology, or public health control of outbreaks of Nipah virus. The research priorities are organised into four main sections: cross-cutting issues (for those that apply to more than one category of medical countermeasures), diagnostics, therapeutics, and vaccines. The strategic goals and milestones identified in each section focus on key achievements that are needed over the next 6 years to ensure that the necessary tools are available for rapid response to future outbreaks of Nipah virus or related henipaviruses.

10.
PLoS Pathog ; 5(7): e1000536, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19649327

RESUMEN

In July and September 2007, miners working in Kitaka Cave, Uganda, were diagnosed with Marburg hemorrhagic fever. The likely source of infection in the cave was Egyptian fruit bats (Rousettus aegyptiacus) based on detection of Marburg virus RNA in 31/611 (5.1%) bats, virus-specific antibody in bat sera, and isolation of genetically diverse virus from bat tissues. The virus isolates were collected nine months apart, demonstrating long-term virus circulation. The bat colony was estimated to be over 100,000 animals using mark and re-capture methods, predicting the presence of over 5,000 virus-infected bats. The genetically diverse virus genome sequences from bats and miners closely matched. These data indicate common Egyptian fruit bats can represent a major natural reservoir and source of Marburg virus with potential for spillover into humans.


Asunto(s)
Quirópteros/virología , Enfermedad del Virus de Marburg/virología , Marburgvirus/genética , Animales , Anticuerpos Antivirales/sangre , Antígenos Virales/sangre , Quirópteros/sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Inmunohistoquímica , Hígado/química , Hígado/virología , Masculino , Enfermedad del Virus de Marburg/sangre , Marburgvirus/aislamiento & purificación , Filogenia , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Uganda
11.
J Infect Dev Ctries ; 2(1): 3-23, 2008 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-19736383

RESUMEN

Hantaviruses have the potential to cause two different types of diseases in human: hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). HFRS, initially described clinically at the turn of the 20th century, occurs endemically in the Asian and European continents, while HPS, recognized as a clinical entity since 1993, represents the prototype of emerging diseases occurring in the Western hemisphere. Approximately 150,000 to 200,000 cases of HFRS are hospitalized each year world wide, with most of the cases occurring in the developing countries. The case fatality rate of HFRS varies from <1% to 12% depending on the viruses. Although HPS is much smaller in number than HFRS, with approximately 200 HPS cases per year in the Americas, the average case fatality rate is 40%. The reported cases of hantaviral infection is increasing in many countries and new hantavirus strains have been increasingly identified worldwide, which constitutes a public health problem of increasing global concern. Hantaviral infection might be underestimated due to its asymptomatic and non-specific mild infection, and the lack of simple standardized laboratory diagnostics in hospitals, especially in the developing countries. This review summarizes the current knowledge on virology, epidemiology, clinical manifestation, laboratory diagnostics, treatment and prevention of hantaviruses and hantaviral infections.


Asunto(s)
Salud Global , Infecciones por Hantavirus , Animales , Reservorios de Enfermedades/virología , Orthohantavirus/clasificación , Infecciones por Hantavirus/diagnóstico , Infecciones por Hantavirus/epidemiología , Infecciones por Hantavirus/terapia , Infecciones por Hantavirus/virología , Humanos , Prevalencia , Control de Roedores , Vacunas Virales
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA